FXS individuals have an increase in the synthesis of de novo proteins such as ERK1/2 and Akt, involved in the mTOR pathway, which is known for regulating the expression of key proteins involved in neurodevelopmental and neurodegenerative diseases, such as FXS, ASD, T2D, and AD. This evidence concerns the gene AKT1 and fragile X syndrome.